Skip to main content
Erschienen in: Clinical and Translational Allergy 3/2014

Open Access 01.07.2014 | Poster presentation

Multifocal fixed drug eruption due to ornidazole

verfasst von: Fevzi Demirel, Abdullah Baysan, Sait Yesillik, Ozgur Kartal, Mustafa Gulec, Ugur Musabak, Osman Sener

Erschienen in: Clinical and Translational Allergy | Sonderheft 3/2014

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN

Introduction

Ornidazole, a synthetic nitroimidazole derivative, is widely used in clinical practice. Ornidazol has low rate of side effects, but sometimes may cause significant allergic reactions such as fixed drug eruption (FDE). We describe a case of multifocal FDE caused by ornidazole.

Case report

A 40-year old woman applied to the Immunology and Allergy clinic with pruritic erythematous lesions over the lateral sides of both arms and right hip within 30 minutes after the ingestion of ornizadole 500 mg tablet. She reported that five recurrent reactions emerged with the same drug on the same locations previously, and their severity was increased consecutively. She was prescribed ornidazole for trichomonal vaginitis and she never warned physicians about the previous drug reactions. In view of the personal history and physical examination a diagnosis of FDE due to ornidazole was diagnosed. After a month from the last reaction allergy tests including prick, intradermal and patch tests were performed with ornidazole and metranidazole. Skin tests with 1/100 W/vol and 1/10 W/vol concentrations and undiluted form of the two drugs were negative. The patch tests consisted of the same drug concentrations were applied to the lesion site on her left arm. Readings were done at 48 hour later and positive results were obtained with ornidazole but not with metranidazole. A placebo controlled oral challenge was performed with metranidazole and no reaction was observed. Following, she contunied to receive metranidazole without any problem.

Conclusion

The lesionel patch test is more diagnostic than other allergy tests at recürrent fixed drug reactions. The patch test may be performed with the same drug solutions as performed on skin prick and intradermal tests without adding petrolatum. Although metronidazole and ornidazole are chemically related drugs, and metranidazole is known more susceptible to cause FDE, metranidazole may be an alternative drug to ornidazole like our case.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​4.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
download
DOWNLOAD
print
DRUCKEN
Metadaten
Titel
Multifocal fixed drug eruption due to ornidazole
verfasst von
Fevzi Demirel
Abdullah Baysan
Sait Yesillik
Ozgur Kartal
Mustafa Gulec
Ugur Musabak
Osman Sener
Publikationsdatum
01.07.2014
Verlag
BioMed Central
Erschienen in
Clinical and Translational Allergy / Ausgabe Sonderheft 3/2014
Elektronische ISSN: 2045-7022
DOI
https://doi.org/10.1186/2045-7022-4-S3-P99

Weitere Artikel der Sonderheft 3/2014

Clinical and Translational Allergy 3/2014 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

29.05.2024 Hörstörungen Nachrichten

Hört jemand im Alter schlecht, nimmt das Hirn- und Hippocampusvolumen besonders schnell ab, was auch mit einem beschleunigten kognitiven Abbau einhergeht. Und diese Prozesse scheinen sich unabhängig von der Amyloidablagerung zu ereignen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.